Can AstraZeneca PLC (NASDAQ:AZN) Offer Investors Safety?

AstraZeneca PLC (NASDAQ:AZN) has a beta of 0.53, a 12-month trailing P/E ratio of 41.55, and a growth ratio of 2.06. The stock’s Relative Strength Index (RSI) is 46.86, with weekly volatility at 1.27% and ATR at 0.89. The AZN stock’s 52-week price range has touched low of $36.15 and a $64.94 high. Its shares traded lower over the last trading session, losing -0.04% on 02/22/21. The shares fell to a low of $50.36 before closing at $50.57. Intraday shares traded counted 10.77 million, which was 11.83% higher than its 30-day average trading volume of 12.21M. AZN’s previous close was $50.59 while the outstanding shares total 2.62B.

Investors have identified the Drug Manufacturers – General company AstraZeneca PLC as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $135.50 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

AstraZeneca PLC (AZN) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For AZN, the company has in raw cash 7.83 billion on their books with 2.19 billion currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 19.54 billion total, with 20.31 billion as their total liabilities.

Having a look at the company’s valuation, the company is expected to record 3.94 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on AZN sounds very interesting.

Is the stock of AZN attractive?

In the last 6 months, insiders have changed their ownership in shares of company stock by 0.50%.

19 out of 25 analysts covering the stock have rated it a Buy, while 3 have maintained a Hold recommendation on AstraZeneca PLC. 1 analysts has assigned a Sell rating on the AZN stock. The 12-month mean consensus price target for the company’s shares has been set at $62.35.

LEAVE A REPLY

Please enter your comment!
Please enter your name here